

May 22, 2020

♦ Treatment of coagulopathy in COVID-19 patients: protocol for a scoping review

Hirotaka Mori¹, Hiroshi Ohkawara¹, Takayuki Ikezoe¹, Ryuichi Togawa², Mami Rikimaru², Yoko Shibata²

¹Department of Hematology, Fukushima Medical University, Fukushima 960-1295, Japan,

²Department of Respiratory Medicine, Fukushima Medical University, Fukushima 960-1295, Japan

1 Works for me dx.doi.org/10.17504/protocols.io.bgrpjv5n

Department of Hematology, Fukushima Medical University, Fuku...

ABSTRACT

Background

Hirotaka Mori

Coronavirus infection disease 2019 (COVID-19) patients have a significant association with coagulopathy and disseminated intravascular coagulation contributing to high mortality. The treatment of COVID-19 and the control of coagulopathy are the primary concern. Although the evidence of anticoagulants in COVID-19 patients with coagulopathy is compiling, there is no scoping review to systematically map the anticoagulants used in this area and to identify the existing gaps between investigated treatment and not. The objective is to conduct a scoping review of available evidence on the anticoagulants in COVID-19 patients with coagulopathy.

Methodo

For conducting the scoping review protocol, we will use a scoping review methodology in the Joanna Briggs Institute manual. This methodology has a five-stage approach:

(1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collating, summarize and report the results. We also will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews to assess the results.

Ethics and dissemination

Because this is a review of the literature, ethics approval is not indicated. We will disseminate the findings from this review in publications in peer-reviewed journals.

ATTACHMENTS

protocol.pdf



05/22/2020